Highlights of This Issue 1619

EDITORIAL
1621 Toward a New Era in Cancer Treatment: Message from the New Editor-in-Chief
John C. Reed

SPOTLIGHT IN CLINICAL RESPONSE
1623 Sustained Remission of Multicentric Castleman Disease in Children Treated with Tocilizumab, an Anti-Interleukin-6 Receptor Antibody
Caroline Galeotti, Adeline Boucheron, Séverine Guillaume, and Isabelle Kone-Paut

REVIEW
1627 DNA Damage Repair Pathways in Cancer Stem Cells
Marcello Maugeri-Saccà, Monica Bartucci, and Ruggero De Maria

THERAPEUTIC DISCOVERY
1637 SAR131675, a Potent and Selective VEGFR-3–TK Inhibitor with Antilymphangiogenic, Antitumoral, and Antimetastatic Activities
Antoine Alam, Isabelle Blanc, Geneviève Gueguen-Dorbes, Olivier Duclos, Jacques Bonnin, Pauline Barron, Marie-Claude Laplace, Gaelle Morin, Florence Gaujarengues, Frédérique Dol, Jean-Pascal Héral, Paul Schaeffer, Pierre Savi, and Françoise Bonomo

MEDI0639: A Novel Therapeutic Antibody Targeting DLL4 Modulates Endothelial Cell Function and Angiogenesis In Vivo

1650 Cotargeting Stress-Activated Hsp27 and Autophagy as a Combinatorial Strategy to Amplify Endoplasmic Reticular Stress in Prostate Cancer
Masafumi Kumano, Junya Furukawa, Masaki Shiotani, Anousheh Zardan, Fan Zhang, Eliana Beraldin, Romina M. Wiedmann, Ladan Fazli, Amina Zoubeidi, and Martin E. Gleaves

1661 A Small-Molecule Inhibitor of Glucose Transporter 1 Downregulates Glycolysis, Induces Cell-Cycle Arrest, and Inhibits Cancer Cell Growth In Vitro and In Vivo
Yi Liu, Yan Yan Cao, Weihe Zhang, Stephen Bergmeier, Yanrong Qian, Huzoor Akbar, Robert Colvin, Juan Ding, Lingying Tong, Shiyoug Wu, Jennifer Hines, and Xiaohuouo Chen

1672 Targeting Subcellular Localization through the Polo-Box Domain: Non-ATP Competitive Inhibitors Recapitulate a PLK1 Phenotype
Campbell Mcllnnes, Kara Estes, Merissa Baxter, Zhengguan Yang, Doaa Boshra Farag, Paul Johnston, John S. Lazo, Jianjun Wang, and Michael D. Wyatt

1683 New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib
Yinxiang Wei, Yuanfang Ma, Qing Zhao, Zhiquang Ren, Yan Li, Tingjun Hou, and Hui Peng

1693 Growth Inhibition of Ovarian Tumor–Initiating Cells by Niclosamide
Yi-Te Yo, Ya-Wen Lin, Yu-Chi Wang, Curt Balch, Rui-Lan Huang, Michael W.Y. Chan, Huey-Kang Sytwu, Chi-Kuan Chen, Cheng-Chang Chang, Kenneth P. Nephew, Tim Huang, Mu-Hsien Yu, and Hung-Cheng Lai
PRECLINICAL DEVELOPMENT

1713 REST Is a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma Pete Taylor, Jason Fangusaro, Veena Rajaram, Stewart Goldman, Irene B. Helenowsk, Tobey MacDonald, Martin Hasselblatt, Lars Riedemann, Alvaro Laureano, Laurence Cooper, and Vidya Gopalakrishnan


1735 Molecular Mechanisms Involved in the Synergistic Interaction of the EZH2 Inhibitor 3-Deazaneplanocin A with Gemcitabine in Pancreatic Cancer Cells Amir Avan, Francesco Crea, Elisa Paolicchi, Nicola Funel, Elena Galvani, Victor E Marquez, Richard J. Honeywell, Romano Danesi, Godefrieds J. Peters, and Elisa Giovannetti


1758 Targeting the PI3K/mTOR Axis, Alone and in Combination with Autophagy Blockade, for the Treatment of Malignant Peripheral Nerve Sheath Tumors Markus P. Ghadimi, Gonzalo Lopez, Keila E. Torres, Roman Belousov, Eric D. Young, Jeffery Liu, Kari J. Brewer, Aviad Hoffman, Kristelle Lusby, Alexander J. Lazar, Raphael E. Pollock, and Dina Lev

1770 Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors Michael C. Heinrich, Adrian Marino-Enriquez, Ajia Presnell, Rachel S. Donsky, Diana J. Griffith, Arin McKinley, Janice Patterson, Takahiro Taguchi, Cher-Wei Liang, and Jonathan A. Fletcher

1781 The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells Heather J. Landau, Samuel C. McNeely, Jayasree S. Nair, Raymond L. Comenzo, Takashi Asai, Hillel Friedman, Suresh C. Jhanwar, Stephen D. Nimer, and Gary K. Schwartz

1789 Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K Joanne M. Munck, Michael A. Batey, Yan Zhao, Helen Jenkins, Caroline J. Richardson, Celine Cano, Michele Tavecchio, Jody Barbeau, Julia Bardos, Liam Cornell, Roger J. Griffin, Keith Meneer, Andrew Slade, Pia Thommes, Niall M.B. Martin, David R. Newell, Graeme C.M. Smith, and Nicola J. Curtin


1809 CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma Licun Wu, Zhihong Yun, Tetsuzo Tagawa, Katrina Rey-McIntyre, and Marc de Perrot
MOLECULAR MEDICINE IN PRACTICE

1820
Phase I Study of Pazopanib in Combination with Paclitaxel and Carboplatin Given Every 21 Days in Patients with Advanced Solid Tumors
Howard A. Burris III, Afshin Dowlati, Rebecca A. Moss, Jeffrey R. Infante, Suzanne F. Jones, David R. Spigel, Kelly T. Levinson, Diana Lindquist, Shelby D. Gainer, Mohammed M. Dar, A. Benjamin Suttle, Howard A. Ball, and Antoinette R. Tan

1829
Inhibition of Dendritic Cell Maturation by the Tumor Microenvironment Correlates with the Survival of Colorectal Cancer Patients following Bevacizumab Treatment
Adriana J. Michielsen, Sinead Noonan, Petra Martin, Miriam Tosetto, Joseph Marry, Monika Biniecka, Aoife A. Maguire, John M. Hyland, Kieran D. Sheahan, Diarmuid P. O’Donoghue, Hugh E. Mulcahy, David Fennelly, Elizabeth J. Ryan, and Jacintha N. O’Sullivan

ABOUT THE COVER

The polo-box domain (PBD) has critical roles in the mitotic functions of PLK1. Fragment ligated inhibitory peptides (FLIP) were generated with comparable affinity to peptide PBD inhibitors and possess antiproliferative phenotypes in cells consistent with the observed decrease in PLK1 centrosomal localization. FLIPs induced monopolar and multipolar spindles, in contrast to previously reported small molecule PBD inhibitors that display phenotypes only partially representative of PLK1 knockdown. PBD inhibitors retain high specificity for PLK1 over PLK3 and show the promise of non-ATP competitive kinase inhibitors as antitumor therapeutics. For details, see the article by McInnes and colleagues on page 1683.
Molecular Cancer Therapeutics

11 (8)


Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/11/8

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.